Delcath Systems Announces First Patient Dosed in Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Breast Cancer

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/22/2026

1. SPY
2. WBD
3. PSKY
4. NVDA
5. TSLA
6. USO
7. AMD
8. META
9. AMC
10. ACN

Go back to Delcath Systems Announces First Patient Dosed in Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Breast Cancer
DELCATH SYSTEMS (NASDAQ: DCTH) Delayed: 16.11 --0 (-0%)
Previous Close $16.11    52 Week High $4.72 
Open $16.25    52 Week Low $0.22 
Day High $16.25    P/E N/A 
Day Low $15.87    EPS $-102.40 
Volume 365,510